Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of IFX-1 in moderate to severe hidradenitis suppurativa
2017-004501-40Phase 2Completed
- Sponsor
- InflaRx
- Start
- Feb 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing IFX-1 with Placebo (2 arms). Primary endpoint: HiSCR response at Week 16. Started Feb 2018; status: completed.
02
Drugs
vilobelimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2017-004501-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004501-40.